Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18974967 | 0.90 | NR4A2 (0.35) | — | |
| SCHEMBL18975231 | 0.90 | JAK3 (0.38) | RXFP1JAK3 | |
| SCHEMBL18975215 | 0.89 | JAK3 (0.34) | RAB9AJAK3 | |
| SCHEMBL18975248 | 0.89 | MTNR1A (0.38) | RXFP1JAK3KMT2AGAANPSR1 | |
| SCHEMBL18975057 | 0.82 | KCNH2 (0.40) | JAK3KMT2AKDM4EMAPK1 | |
| SCHEMBL18975230 | 0.81 | JAK3 (0.35) | JAK3 | |
| SCHEMBL18974975 | 0.81 | KMT2A (0.38) | KMT2AKDM4E | |
| SCHEMBL18975224 | 0.81 | KMT2A (0.38) | KMT2AKDM4EMAPK1 | |
| SCHEMBL18975204 | 0.80 | JAK3 (0.37) | JAK3 | |
| SCHEMBL18975507 | 0.80 | NR4A2 (0.42) | RAB9AJAK3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNA7, CHRNA2, CHRNA6 | RAB9A 433/4885RXFP1 696/4885JAK3 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.